• Pimozide was compared with carbamazepine in a double-blind crossover trial in 48 patients with trigeminal neuralgia who were refractory to medical therapy. Pimozide treatment produced greater reduction in trigeminal neuralgia symptoms than carbamazepine treatment. All of the pimozide-treated patients improved, while only 56% of carbamazepine-treated patients were relieved of their pain. Although both drugs provoked some adverse effects, it was not necessary to interrupt the trial in any case. After this 24-week trial, all patients began receiving pimozide and were followed up according to an open-label study design. In all cases, the pimozide dosage was progressively reduced until the minimal effective dose was reached. Central and peripheral mechanisms that may underlie pimozide-induced improvement are discussed.
Lechin F, van der Dijs B, Lechin ME, et al. Pimozide Therapy for Trigeminal Neuralgia. Arch Neurol. 1989;46(9):960–963. doi:10.1001/archneur.1989.00520450030015
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: